Eurydiki Michalis

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Meletios Α. Dimopoulos, Ramón García‐Sánz, Maria Gavriatopoulou et al. · Blood · 2013 · 207 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy

Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou et al. · International Journal of Cancer · 2011 · 182 citations · Full text

Medicine, Hematology, Oncology +17

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents

Meletios Α. Dimopoulos, Sosana Delimpasi, Eirini Katodritou et al. · Annals of Oncology · 2013 · 157 citations

Medicine, Hematology, Nephrology +8

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

Evangelos Terpos, Eirini Katodritou, Anastasia Pouli et al. · European Journal Of Haematology · 2010 · 145 citations

Medicine, Oncology, Chemotherapy +11

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

Efstathios Kastritis, Evangelos Terpos, Maria Gavriatopoulou et al. · Blood · 2012 · 90 citations

Medicine, Pharmacology, Pharmacotherapy +9